Merck halts late-stage Alzheimer’s trial due to lack of efficacy
Merck announced late Tuesday that it has stopped one of two late-stage Alzheimer's trials after the external data monitoring committee determined that its BACE1 inhibitor had “virtually no chance of finding a positive clinical effect” in mild-to-moderate AD.